An open label, multicenter, single arm phase II study of oral GW572016 as single agent therapy in subjects with advanced or metastatic breast cancer who have progressed while receiving Herceptin containing regimens

Trial Profile

An open label, multicenter, single arm phase II study of oral GW572016 as single agent therapy in subjects with advanced or metastatic breast cancer who have progressed while receiving Herceptin containing regimens

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Apr 2015

At a glance

  • Drugs Lapatinib (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 21 Nov 2009 New source identified and integrated (M.D. Anderson Cancer Center, 2003-0414).
    • 04 Nov 2008 Updated from ClinicalTrials.gov record.
    • 04 Nov 2008 Updated from ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top